Abexinostat (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Abexinostat" in English language version.

refsWebsite

Global rank English rank

9nih.gov

4^th place

7doi.org

2^nd place

2cancer.gov

1,684^th place

1,350^th place

2semanticscholar.org

11^th place

8^th place

1who.int

195^th place

302^nd place

1web.archive.org

1^st place

1pharmacyclics.com

low place

1harvard.edu

18^th place

17^th place

1targetedonc.com

low place

1ashpublications.org

low place

1worldcat.org

5^th place

ashpublications.org

Ribrag, Vincent; Kim, Won Seog; Bouabdallah, Reda; Lim, Soon Thye; Coiffier, Bertrand; Felloussi, Zakia; Kloos, Ioana; Luan, Ying; Graef, Thorsten; Morschhauser, Franck (2015-12-03). "Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study". Blood. 126 (23): 256. doi:10.1182/blood.V126.23.256.256. ISSN 0006-4971. Retrieved 2024-02-14.

cancer.gov

"Abexinostat". NCI Cancer Dictionary.
"NCI Drug Dictionary". National Cancer Institute.

doi.org

Bhalla, S; Balasubramanian, S; David, K; Sirisawad, M; Buggy, J; Mauro, L; Prachand, S; Miller, R; Gordon, LI; Evens, AM (2009). "PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells". Clinical Cancer Research. 15 (10): 3354–65. doi:10.1158/1078-0432.CCR-08-2365. PMC 2704489. PMID 19417023.
Lopez, G; Liu, J; Ren, W; Wei, W; Wang, S; Lahat, G; Zhu, QS; Bornmann, WG; McConkey, DJ; Pollock, RE; Lev, DC (2009). "Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma". Clinical Cancer Research. 15 (10): 3472–83. doi:10.1158/1078-0432.CCR-08-2714. PMID 19417021. S2CID 18862692. (Erratum: doi:10.1158/1078-0432.CCR-15-0351, PMID 25833311. If the erratum has been checked and does not affect the cited material, please replace {{erratum|...}} with {{erratum|...|checked=yes}}.)
Rivera-Del Valle, N; Gao, S; Miller, CP; Fulbright, J; Gonzales, C; Sirisawad, M; Steggerda, S; Wheler, J; Balasubramanian, S; Chandra, J (2010). "PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells". International Journal of Cell Biology. 2010: 207420. doi:10.1155/2010/207420. PMC 2817379. PMID 20145726.
Yang, C; Choy, E; Hornicek, FJ; Wood, KB; Schwab, JH; Liu, X; Mankin, H; Duan, Z (2011). "Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells". Cancer Chemotherapy and Pharmacology. 67 (2): 439–46. doi:10.1007/s00280-010-1344-7. PMID 20461381. S2CID 1344662.
Buggy, JJ; Cao, ZA; Bass, KE; Verner, E; Balasubramanian, S; Liu, L; Schultz, BE; Young, PR; Dalrymple, SA (2006). "CRA-024781: A novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo". Molecular Cancer Therapeutics. 5 (5): 1309–17. doi:10.1158/1535-7163.MCT-05-0442. PMID 16731764.
Adimoolam, S; Sirisawad, M; Chen, J; Thiemann, P; Ford, JM; Buggy, JJ (2007). "HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination". Proceedings of the National Academy of Sciences of the United States of America. 104 (49): 19482–7. Bibcode:2007PNAS..10419482A. doi:10.1073/pnas.0707828104. PMC 2148315. PMID 18042714.
Ribrag, Vincent; Kim, Won Seog; Bouabdallah, Reda; Lim, Soon Thye; Coiffier, Bertrand; Felloussi, Zakia; Kloos, Ioana; Luan, Ying; Graef, Thorsten; Morschhauser, Franck (2015-12-03). "Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study". Blood. 126 (23): 256. doi:10.1182/blood.V126.23.256.256. ISSN 0006-4971. Retrieved 2024-02-14.

harvard.edu

ui.adsabs.harvard.edu

Adimoolam, S; Sirisawad, M; Chen, J; Thiemann, P; Ford, JM; Buggy, JJ (2007). "HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination". Proceedings of the National Academy of Sciences of the United States of America. 104 (49): 19482–7. Bibcode:2007PNAS..10419482A. doi:10.1073/pnas.0707828104. PMC 2148315. PMID 18042714.

nih.gov

pubmed.ncbi.nlm.nih.gov

Bhalla, S; Balasubramanian, S; David, K; Sirisawad, M; Buggy, J; Mauro, L; Prachand, S; Miller, R; Gordon, LI; Evens, AM (2009). "PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells". Clinical Cancer Research. 15 (10): 3354–65. doi:10.1158/1078-0432.CCR-08-2365. PMC 2704489. PMID 19417023.
Lopez, G; Liu, J; Ren, W; Wei, W; Wang, S; Lahat, G; Zhu, QS; Bornmann, WG; McConkey, DJ; Pollock, RE; Lev, DC (2009). "Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma". Clinical Cancer Research. 15 (10): 3472–83. doi:10.1158/1078-0432.CCR-08-2714. PMID 19417021. S2CID 18862692. (Erratum: doi:10.1158/1078-0432.CCR-15-0351, PMID 25833311. If the erratum has been checked and does not affect the cited material, please replace {{erratum|...}} with {{erratum|...|checked=yes}}.)
Rivera-Del Valle, N; Gao, S; Miller, CP; Fulbright, J; Gonzales, C; Sirisawad, M; Steggerda, S; Wheler, J; Balasubramanian, S; Chandra, J (2010). "PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells". International Journal of Cell Biology. 2010: 207420. doi:10.1155/2010/207420. PMC 2817379. PMID 20145726.
Yang, C; Choy, E; Hornicek, FJ; Wood, KB; Schwab, JH; Liu, X; Mankin, H; Duan, Z (2011). "Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells". Cancer Chemotherapy and Pharmacology. 67 (2): 439–46. doi:10.1007/s00280-010-1344-7. PMID 20461381. S2CID 1344662.
Buggy, JJ; Cao, ZA; Bass, KE; Verner, E; Balasubramanian, S; Liu, L; Schultz, BE; Young, PR; Dalrymple, SA (2006). "CRA-024781: A novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo". Molecular Cancer Therapeutics. 5 (5): 1309–17. doi:10.1158/1535-7163.MCT-05-0442. PMID 16731764.
Adimoolam, S; Sirisawad, M; Chen, J; Thiemann, P; Ford, JM; Buggy, JJ (2007). "HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination". Proceedings of the National Academy of Sciences of the United States of America. 104 (49): 19482–7. Bibcode:2007PNAS..10419482A. doi:10.1073/pnas.0707828104. PMC 2148315. PMID 18042714.

ncbi.nlm.nih.gov

Bhalla, S; Balasubramanian, S; David, K; Sirisawad, M; Buggy, J; Mauro, L; Prachand, S; Miller, R; Gordon, LI; Evens, AM (2009). "PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells". Clinical Cancer Research. 15 (10): 3354–65. doi:10.1158/1078-0432.CCR-08-2365. PMC 2704489. PMID 19417023.
Rivera-Del Valle, N; Gao, S; Miller, CP; Fulbright, J; Gonzales, C; Sirisawad, M; Steggerda, S; Wheler, J; Balasubramanian, S; Chandra, J (2010). "PCI-24781, a Novel Hydroxamic Acid HDAC Inhibitor, Exerts Cytotoxicity and Histone Alterations via Caspase-8 and FADD in Leukemia Cells". International Journal of Cell Biology. 2010: 207420. doi:10.1155/2010/207420. PMC 2817379. PMID 20145726.
Adimoolam, S; Sirisawad, M; Chen, J; Thiemann, P; Ford, JM; Buggy, JJ (2007). "HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination". Proceedings of the National Academy of Sciences of the United States of America. 104 (49): 19482–7. Bibcode:2007PNAS..10419482A. doi:10.1073/pnas.0707828104. PMC 2148315. PMID 18042714.

pharmacyclics.com

"Abexinostat HCl (PCI-24781), PanHDAC-inhibitor". Pharmacyclics. Archived from the original on 2013-10-27.

semanticscholar.org

api.semanticscholar.org

Lopez, G; Liu, J; Ren, W; Wei, W; Wang, S; Lahat, G; Zhu, QS; Bornmann, WG; McConkey, DJ; Pollock, RE; Lev, DC (2009). "Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma". Clinical Cancer Research. 15 (10): 3472–83. doi:10.1158/1078-0432.CCR-08-2714. PMID 19417021. S2CID 18862692. (Erratum: doi:10.1158/1078-0432.CCR-15-0351, PMID 25833311. If the erratum has been checked and does not affect the cited material, please replace {{erratum|...}} with {{erratum|...|checked=yes}}.)
Yang, C; Choy, E; Hornicek, FJ; Wood, KB; Schwab, JH; Liu, X; Mankin, H; Duan, Z (2011). "Histone deacetylase inhibitor (HDACI) PCI-24781 potentiates cytotoxic effects of doxorubicin in bone sarcoma cells". Cancer Chemotherapy and Pharmacology. 67 (2): 439–46. doi:10.1007/s00280-010-1344-7. PMID 20461381. S2CID 1344662.

targetedonc.com

"FDA Grants Fast Track Designation to Abexinostat for Fourth-Line Follicular Lymphoma". Targeted Oncology. 2019-09-23. Retrieved 2024-02-14.

web.archive.org

"Abexinostat HCl (PCI-24781), PanHDAC-inhibitor". Pharmacyclics. Archived from the original on 2013-10-27.

who.int

"International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). 2011.

worldcat.org

search.worldcat.org

Ribrag, Vincent; Kim, Won Seog; Bouabdallah, Reda; Lim, Soon Thye; Coiffier, Bertrand; Felloussi, Zakia; Kloos, Ioana; Luan, Ying; Graef, Thorsten; Morschhauser, Franck (2015-12-03). "Safety and Efficacy of Abexinostat, a Pan-Histone Deacetylase (HDAC) Inhibitor, in Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Results of an Ongoing Phase 2 Study". Blood. 126 (23): 256. doi:10.1182/blood.V126.23.256.256. ISSN 0006-4971. Retrieved 2024-02-14.